Share: 
Omnicef® (cefdinir) is considered a pregnancy Category B medicine by the U.S. Food and Drug Administration (FDA), which means that it has not been studied in pregnant women. However, when studied in pregnant animals, Omnicef showed no negative effects on the fetus.
The FDA uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category B is given to medicines that do not cause side effects to the fetus in animal studies but no human studies in pregnant women have been conducted.
However, it is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category B medicine may be given to a pregnant woman if the healthcare provider believes that the benefits to the mother outweigh any possible risks to the unborn child.
If you are taking Omnicef and pregnancy occurs, let your healthcare provider know. He or she will consider the benefits and risks of Omnicef during pregnancy before making a recommendation for your particular situation.
Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
Other Articles in This eMedTV Presentation
eMedTV Links
Copyright © 2006-2013 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.
This site complies with the HONcode standard for trustworthy health information:
verify here.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.
This site complies with the HONcode standard for trustworthy health information:
verify here.